Im not sure if I missed it, but are the patients continuing to stay on the drugs post trial?
The reason I ask is that it, if they rollover the patients from the phase 2 group into the phase 3 study, perhaps including the ones on placebo, it. might speed up recruitment? But it would skew the data if patients were already on the drug vs new ones being recruited?
The announcement this morning did say they look forward to reporting toppling data mid year 2025. June?
I suspect they might be looking at putting a phase 3 together perhaps even a phase 1 for Parkinson's?
Im just hypothesising as to what they might be doing behind the scenes for the next 2 months apart from unpacking data.....
ATH Price at posting:
1.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)